There are currently 73 active clinical trials seeking participants for Metastatic Cancer research studies. The states with the highest number of trials for Autism participants are California, Ohio, Michigan and Illinois.
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
NCT05840510
Recruiting
This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Research Site, Cleveland, Ohio +2 locations
Conditions: Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
NCT05065736
Recruiting
The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Metastatic Cancer, Carcinoma, Adenocarcinoma
Register for Updates
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
NCT04090528
Recruiting
This trial will evaluate the use of one versus two DNA vaccines, delivered concurrently with PD-1 blockade using pembrolizumab followed by treatment with pembrolizumab alone, and delivered over a prolonged period of time (for a maximum of 2 years (32 cycles) or until radiographic progression) on the treatment of castrate-resistant, metastatic prostate cancer. The hypothesis to be tested is that delivering two vaccines with PD-1 blockade will elicit a greater frequency and magnitude of tumor-dire... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Washington University Siteman Cancer Center, Saint Louis, Missouri +1 locations
Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
Register for Updates
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045
Recruiting
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: SCRI HealthOne, Denver, Colorado +6 locations
Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor
Register for Updates
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
NCT05678010
Recruiting
The purpose of this study is to find out whether AZD1390 combined with stereotactic body radiation therapy/SBRT is a safe treatment for people with metastatic solid tumor cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey +4 locations
Conditions: Solid Tumor, Metastatic Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Tumor, Metastatic Cancer
Register for Updates
Randomized Clinical Trial of a Multi-Modal Palliative Care Intervention
NCT04773639
Recruiting
Adults diagnosed with metastatic cancer commonly experience depression and anxiety symptoms, which can interfere with advance care planning. This randomized clinical trial evaluates a novel, piloted, primary palliative care intervention that addresses advance care planning and psychosocial needs of patients with metastatic cancer. The intervention focuses on patients with elevated anxiety and depression (anx/dep) symptoms-those with highest psychosocial needs who may be at greatest risk for adva... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: Rocky Mountain Cancer Centers, Boulder, Colorado
Conditions: Depression, Anxiety, Metastatic Cancer
Register for Updates
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +97 locations
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
NCT04648202
Recruiting
This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Yale University, New Haven, Connecticut +8 locations
Conditions: Advanced Cancer, Metastatic Cancer
Register for Updates
Evaluating Disparities in Precision Oncology
NCT06081517
Recruiting
This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/06/2024
Locations: Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Metastatic Cancer, Advanced Cancer
Register for Updates
A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST 1]
NCT05489237
Recruiting
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: University of Miami, Miami, Florida +8 locations
Conditions: Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
Register for Updates
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047
Recruiting
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 426 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +122 locations
Conditions: Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
Register for Updates
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068
Recruiting
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +34 locations
Conditions: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates